Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Thurs Jan 9th, the US Stock Markets will be closed in observance of a national day of mourning for former President Jimmy Carter. Read the press release here. Regular trading hours will resume tomorrow.

Sana Biotechnology Inc (SANA)

Sana Biotechnology Inc (SANA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 960,057
  • Shares Outstanding, K 223,269
  • Annual Sales, $ 0 K
  • Annual Income, $ -283,260 K
  • EBIT $ -312 M
  • EBITDA $ -288 M
  • 60-Month Beta 1.45
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.25

Options Overview Details

View History
  • Implied Volatility 226.80% ( -179.69%)
  • Historical Volatility 295.19%
  • IV Percentile 81%
  • IV Rank 20.75%
  • IV High 833.42% on 01/06/25
  • IV Low 67.95% on 10/07/24
  • Put/Call Vol Ratio 0.58
  • Today's Volume 64,125
  • Volume Avg (30-Day) 3,223
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 32,829
  • Open Int (30-Day) 33,465

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.25
  • Number of Estimates 4
  • High Estimate -0.21
  • Low Estimate -0.31
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.52 +182.89%
on 12/30/24
7.30 -41.10%
on 01/08/25
+2.00 (+86.96%)
since 12/06/24
3-Month
1.52 +182.89%
on 12/30/24
7.30 -41.10%
on 01/08/25
+0.22 (+5.39%)
since 10/08/24
52-Week
1.52 +182.89%
on 12/30/24
12.00 -64.17%
on 03/01/24
-0.78 (-15.35%)
since 01/08/24

Most Recent Stories

More News
Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SANA : 4.30 (+160.61%)
Sana Biotech Stock Triples After Type 1 Diabetes Trial Wows Analysts: Retail Erupts In Excitement

Citi referred to the data as a "major scientific advance" for type 1 diabetes patients, highlighting the potential for broader applications in the allogeneic field.

SANA : 4.30 (+160.61%)
S&P Futures Slip on Trump Tariff Worries, U.S. ADP Jobs Report and FOMC Minutes in Focus

March S&P 500 E-Mini futures (ESH25) are trending down -0.27% this morning as investors weighed concerns over U.S. tariffs while awaiting the Federal Reserve’s December meeting minutes, comments from...

MSTR : 331.70 (-2.85%)
CALM : 104.73 (+1.01%)
SHEL.LN : 2,613.500 (+1.32%)
PLX.FP : 21.840 (+0.32%)
SANA : 4.30 (+160.61%)
RGTI : 10.04 (-45.41%)
ESH25 : 5,944.75 (-0.24%)
QUBT : 9.91 (-43.34%)
TSLA : 394.94 (+0.15%)
QBTS : 6.10 (-36.13%)
AMD : 121.84 (-4.31%)
EQT.S.DX : 320.300 (+0.72%)
Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

SANA : 4.30 (+160.61%)
Sana Biotechnology Receives FDA Fast Track Designation for SC291 in Treatment of Relapsed/Refractory Systemic Lupus Erythematosus

Sana Biotechnology's SC291 receives FDA Fast Track designation for treating relapsed/refractory systemic lupus erythematosus, with initial data expected in 2025.Quiver AI SummarySana Biotechnology, Inc....

SANA : 4.30 (+160.61%)
Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus

SANA : 4.30 (+160.61%)
Sana Biotechnology to Present at December 2024 Investor Conferences

SANA : 4.30 (+160.61%)
Sana: Q3 Earnings Snapshot

Sana: Q3 Earnings Snapshot

SANA : 4.30 (+160.61%)
Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates

SANA : 4.30 (+160.61%)
Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025

SANA : 4.30 (+160.61%)

Business Summary

Sana Biotechnology Inc. is focused on creating and delivering engineered cells as medicines for patients. The company involved in repairing and controlling genes, replacing missing or damaged cells as well as making its therapies. Sana Biotechnology Inc. is based in SEATTLE.

See More

Key Turning Points

3rd Resistance Point 9.54
2nd Resistance Point 8.42
1st Resistance Point 6.36
Last Price 4.30
1st Support Level 3.18
2nd Support Level 2.06
3rd Support Level N/A

See More

52-Week High 12.00
Fibonacci 61.8% 8.00
Fibonacci 50% 6.76
Fibonacci 38.2% 5.52
Last Price 4.30
52-Week Low 1.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar